Search

everythinglearnresearchcommunity

for

Search:↓

PTD-DBM is a Korean-developed treatment for hair loss, with limited information available and some users testing it personally. A user purchased PTD-DBM for $115 and plans to test it on their temples, but its effectiveness and authenticity remain uncertain.

GT20029 is anticipated to start phase III trials in Q3 2026, with potential public availability around 2029-2030.

The user has been using finasteride for 5 months without hair regrowth or loss and is considering adding dermarolling to their regimen. They are seeking advice on the effectiveness of finasteride with dermarolling, the type of dermaroller to use, aftercare products, and concerns about shedding from dermarolling alone.

The conversation discusses GT20029 as a potential hair loss treatment that could act like a cure by targeting androgen receptors in scalp hair follicles. Specific treatments mentioned include GT20029, with a user expressing hope that it could make male pattern baldness obsolete.

GT20026 is discussed as a potential treatment for hair loss that targets androgen receptors without affecting hormone levels, but it may not promote significant regrowth. It is expected to be available by 2028, with other treatments like Breezula and Clascoterone also mentioned.

A user's experience with the Big 3 (minoxidil, finasteride and RU58841) hair loss treatment along with dermarolling. The dermaroller pin was 1.5mm used once per week and drew some blood but not a lot.

An arthritis drug, baricitinib, is discussed as a potential treatment for autoimmune alopecia, not androgenetic alopecia. Ritlecitinib is also mentioned as a possible treatment for scarring alopecia.

A 28-year-old shared surprising hair regrowth progress after 20 days using topical minoxidil, micro needling, GHK-cu, and BPC-157 injections. The user noted a significant reduction in their bald spot and overall hair improvement.

The user successfully managed hair regrowth by using a combination of finasteride, dutasteride, minoxidil, and specific shampoos to treat seborrheic dermatitis. They emphasize the importance of maintaining a healthy scalp and are considering food intolerance tests to further address inflammation.

The conversation discusses the effectiveness of dermastamps versus dermarollers for hair loss treatment, with some users preferring dermastamps for precision and less hair damage. One user reports using a dermastamp with minoxidil, while others mention the convenience of dermapens and the cost-effectiveness of dermarollers.

User asks how long RU58841 bottle lasts, inquires about application, quantities, and mixing at home.

Using dutasteride anally as a hair loss treatment, with humorous and satirical comments on its effects and implications.

The conversation discusses hair loss treatment using 1ml of minoxidil twice daily and a 1.5mm dermaroller once a week. One person suggests considering finasteride, while another emphasizes the importance of microneedling in maintaining hair growth.

Breezula (clascoterone) is expected to be available by late 2026, showing good long-term results with minimal side effects. KX-826 (pyrilutamide) acts faster but is still in earlier development stages.

A user is seeking advice on the efficacy and side effects of homemade topical solutions for hair loss, specifically bicalutamide, estradiol, cyproterone acetate, and spironolactone, as they cannot access RU58841 or pyrilutamide.

Verteporfin and BPC-157 are being discussed as potential treatments for hair loss. The conversation also mentions Minoxidil, finasteride, and RU58841.

The user noticed increased hair fullness after using a minoxidil and finasteride oral capsule but is unsure if the 1.25 mg minoxidil dose is sufficient. They are considering switching to a higher dose and are waiting for a dermatologist's advice.

Alternative treatments for hair loss such as Procapil, Redensyl, and Baicapil being compared to Minoxidil, Finasteride, and RU58841.

The conversation is about a user offering free unused Eucapil after switching to finasteride for hair loss treatment. The user did not use Eucapil and is willing to give it away locally or ship it if costs are covered.

Follicum discovered that their drug FOL-005 increased hair count by 12 hairs per cm2 in patients with less than 255 hairs per cm2 and is planning a phase 2b trial. They are currently fundraising for the trial, and the drug may also be effective for women.

OP developed hives after using Kx 826 (Pyrilutamide) 1% twice daily for 3 weeks. The hives appeared on the arms, chest, and groin area.

The conversation is about adding a low dose of pyrilutamide to a hair loss treatment regimen. Specific treatments mentioned include Minoxidil, finasteride, and RU58841.

The conversation is about the quality of RU58841 powder from Shaanxi Laon Biotech. The user is inquiring if anyone has experience with this product.

The conversation discusses the approval of Kintor Pharmaceutical's AR-PROTAC (GT20029) for clinical trials in China for acne and androgenic alopecia. One user expresses optimism about new treatments being developed and seeks clarification on how the new drug works, specifically if it temporarily degrades the AR protein to reduce DHT sensitivity in hair follicles.

The conversation discusses the removal of Breezula phase II 12-month results by Cassiopea and the search for the original data. Concerns were raised about potential negative long-term effects on hair growth, such as androgen receptor upregulation.

The conversation discusses positive initial trial results for GT20029, a topical compound for hair loss that degrades androgen receptors, potentially requiring only weekly application. Participants express hope for this treatment to be more effective and convenient than current options like Minoxidil, Finasteride, and RU58841.

The conversation is about a user experiencing hair shedding after using a brand of RU58841, questioning its effectiveness and safety. Concerns are raised about RU58841 being an abandoned research chemical and the use of heavy oils like castor and argan oil potentially affecting absorption.

SCUBE3 and Amplifica's progress in hair loss treatment is being discussed, with inquiries about their current status and clinical trials. No specific updates or new information are provided in the conversation.

The conversation is about a potential new hair loss treatment called Breezula CB-03-01. Users are discussing updates on its development and sharing personal experiences with making or using it.

P-1075 is a more potent hair growth agent than Minoxidil, but it poses significant heart risks, making it unsafe for use. Despite promising results in macaques, concerns about its cardiotoxicity in rats have halted its development.